CytoDyn Inc.
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$0.32
FAIR PRICE
$0.27
MARGIN
$0.05
P/E Ratio
N/A
Div. Yield
N/A
ROE
38.1%
Exceptional
Market Cap
$423M
Small-cap
NOW AVAILABLE
Get notified when CYDY's fair price changes
Push notifications when CYDY's valuation shifts. Available on iOS and Android.
FPI RATING
Attractive valuation and strong profitability, but volatile earnings pattern.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$0.22
Fair price × 0.80
DISTANCE
32.0%
Price to entry level
At the current price of $0.32, CYDY trades 32.0% above the conservative entry level of $0.22. This entry level represents a 20% margin of safety below the calculated fair price of $0.27 — a buffer that accounts for estimation uncertainty in the valuation model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
Loading chart data...
P/E RATIO HISTORY
Loading chart data...
METHODOLOGY
How we calculate CYDY's fair price
CytoDyn Inc.'s fair price of $0.27 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $0.32, CYDY trades 15.0% above its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting CYDY's risk profile.
RELATIVE · 30%
Comparing CYDY's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for CYDY, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate CYDY's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for CYDY.
Explore on BuliosFAQ
What is the fair price of CYDY?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for CytoDyn Inc. is $0.27. At the current market price of $0.32, CYDY trades 15.0% above its calculated fair value.
Is CYDY overvalued or undervalued?+
CytoDyn Inc. is currently overvalued based on our valuation model. The stock trades at $0.32, which is 15.0% above the fair price of $0.27.
What is the margin of safety for CYDY?+
With a 20% margin of safety applied to the fair price of $0.27, the conservative entry level for CYDY is $0.22. At the current market price of $0.32, the stock trades 32.0% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is CYDY's fair price updated?+
We update fair price calculations for CYDY daily after market close. The current fair price of $0.27 incorporates the latest market data and sector multiples.
What factors affect CYDY's fair price calculation?+
CYDY's fair price of $0.27 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of 38.1%.
Is CYDY a good buy right now?+
At $0.32, CYDY trades 15.0% above our fair value estimate of $0.27. The stock is currently overvalued. ROE stands at 38.1% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.
Does CYDY pay dividends?+
CYDY does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.